Monopar Therapeutics Inc. (MNPR) Return on equity 2016–2025
Monopar Therapeutics Inc. (MNPR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-10.0%FY2025 · since FY2016: -41.9% → -10.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -10.0% | +18.4 pp |
| FY2024 | -28.3% | — |
| FY2019 | -33.5% | +13.2 pp |
| FY2018 | -46.7% | +125.4 pp |
| FY2017 | -172.1% | -130.2 pp |
| FY2016 | -41.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MNPR financial trends
MNPR RevenueMNPR Net incomeMNPR Net marginMNPR Gross profitMNPR Gross marginMNPR Operating incomeMNPR Operating marginMNPR Operating cash flowMNPR Free cash flowMNPR Capital expendituresMNPR Stock buybacksMNPR Dividends paidMNPR Total assetsMNPR Total liabilitiesMNPR Shareholders’ equityMNPR overview →